Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Abbvie Inc Common Stock (ABBV) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 96,140,864
  • Shares Outstanding, K 1,628,540
  • Annual Sales, $ 22,859 M
  • Annual Income, $ 5,144 M
  • 36-Month Beta 1.58
  • Price/Sales 4.21
  • Price/Book 14.89

Price Performance

See More
Period Period Low Period High Performance
1-Month
55.85 +6.41%
on 11/03/16
65.05 -8.64%
on 11/10/16
+2.64 (+4.65%)
since 11/02/16
3-Month
55.06 +7.94%
on 10/28/16
65.33 -9.03%
on 09/23/16
-4.69 (-7.31%)
since 09/02/16
52-Week
50.71 +17.20%
on 01/14/16
68.12 -12.76%
on 08/15/16
+1.71 (+2.96%)
since 12/02/15

Most Recent Stories

More News
Favorable Response Rates Suggest Promise of Ibrutinib (IMBRUVICA®) Combination Therapy in Two Common Types of Non-Hodgkin's Lymphoma

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced encouraging efficacy and safety findings from two separate studies evaluating ibrutinib (IMBRUVICA®) as a combination therapy in...

AbbVie Crohn's Disease Drug Gets Orphan Drug Status in U.S.

AbbVie Inc. (ABBV) announced that the FDA has granted Orphan Drug Designation to its investigational IL-23 inhibitor, risankizumab (ABBV-066; formerly BI 655066), for the treatment of Crohn's disease in...

Momenta/Shire's Humira Biosimilar Meets Study Objective

Momenta (MNTA) announced positive data from a phase III study on M923 for the treatment of moderate-to-severe chronic plaque psoriasis.

Galapagos (GLPG) Filgotinib in Phase III for Crohn's Disease

Galapagos (GLPG) dosed the first patient in the phase III DIVERSITY study on filgotinib for the treatment of Crohn's disease.

The Zacks Analyst Blog Highlights: Amgen, Cisco, NextEra Energy, AbbVie and eBay

The Zacks Analyst Blog Highlights: Amgen, Cisco, NextEra Energy, AbbVie and eBay

J&J (JNJ) Files for Psoriasis Candidate Guselkumab in U.S.

Johnson & Johnson???s (JNJ) subsidiary, Janssen announced the submission of a Biologics License Application (BLA) to the FDA for its pipeline candidate guselkumab for the treatment of adults with moderate...

Top Research Reports for Cisco, Amgen & NextEra Energy

Top Research Reports for Cisco, Amgen & NextEra Energy

Sanofi/Regeneron Present Sarilumab Data at ACR Meeting

Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) announced results from a phase III monotherapy study (SARIL-RA-MONARCH) on sarilumab.

Glaxo (GSK) Presents Phase III Data on Sirukumab & Benlysta

GlaxoSmithKline plc (GSK) reported results from two pivotal phase III studies -- SIRROUND-T and SIRROUND-H.

J&J (JNJ) Stelara Gets Approval in EU for Label Expansion

Johnson & Johnson's (JNJ) subsidiary, Janssen Therapeutics, announced that the European Commission has approved its prescription drug Stelara for the treatment of moderate-to-severely active Crohn's disease...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation...

See More

Support & Resistance

2nd Resistance Point 60.51
1st Resistance Point 59.97
Last Price 59.43
1st Support Level 58.92
2nd Support Level 58.41

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.